Exploring Mid-Air Hand Interaction in Data Visualization.

Interacting with data visualizations without an instrument or touch surface is typically characterized by the use of mid-air hand gestures. While mid-air expressions can be quite intuitive for interacting with digital content at a distance, they frequently lack precision and necessitate a different way of expressing users' data-related intentions. In this work, we aim to identify new designs for mid-air hand gesture manipulations that can facilitate instrument-free, touch-free, and embedded interactions with visualizations, while utilizing the three-dimensional (3D) interaction space that mid-air gestures afford. We explore mid-air hand gestures for data visualization by searching for natural means to interact with content. We employ three studies-an Elicitation Study, a User Study, and an Expert Study, to provide insight into the users' mental models, explore the design space, and suggest considerations for future mid-air hand gesture design. In addition to forming strong associations with physical manipulations, we discovered that mid-air hand gestures can: promote space-multiplexed interaction, which allows for a greater degree of expression; play a functional role in visual cognition and comprehension; and enhance creativity and engagement. We further highlight the challenges that designers in this field may face to help set the stage for developing effective gestures for a wide range of touchless interactions with visualizations.

Advancing social inclusion of people with disabilities through awareness and training activities: A collaborative process between community partners and researchers.

OBJECTIVE: The main objectives were to 1) search and map current disability awareness and training activities in Quebec, Canada, 2) collectively reflect on these practices, and 3) develop a five-year strategic plan. METHODS: We used an integrated knowledge translation approach whereby researchers and community partners were involved in all stages. This project consisted of two sequential phases: 1) an environmental scan (web review and interview) of current practices, and 2) a reflection process with an external expert-facilitator in social transformation. Outcome results and process data are reported. RESULTS: We identified 129 activities (71 training, 58 awareness) from 39 organizations (from 123 organizations initially invited). A wide range of characteristics were collected for each activity which allowed for the identification of gaps. The working group met seven times in one year to discuss results from phase 1 and co-create a five-year strategic plan. Main priorities are 1) the development of a methodology for measuring collective impact and 2) content synchronization of activities. CONCLUSION: Involvement of partners and researchers enabled a concerted and efficient approach to the development of a five-year strategic plan. PRACTICE IMPLICATIONS: A transition committee led by partners will ensure implementation and sustainability of the plan across the province.

Use of the bioMérieux VIDAS troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome.

BACKGROUND: We demonstrate the performance of the bioMérieux VIDAS Troponin I Ultra assay for diagnostic accuracy for detection of myocardial infarction (MI) and risk stratification. METHOD: cTnI was measured in 545 patients from 2 clinical centers with symptoms suggestive of ACS at admission, with an additional specimen at 4-12 h (453 patients). The 99th percentile value (0.01 microg/l) was used to assess clinical accuracy for diagnosis of acute MI. Primary endpoint for risk stratification was first of cardiac event or death in 302 patients (one center) followed for 60 days. RESULTS: 157 (28.8%) patients ruled in for an MI during index hospitalization. Sensitivities and specificities were 88.1% (95% CI 81.9 to 92.4%) and 79.9% (CI 75.5 to 83.6%) for baseline and 100% (CI 96.5 to 100%) and 79.4% (CI 74.4 to 83.4%) for follow-up specimens. ROC curve areas increased from 0.912 (CI 0.879 to 0.944) at baseline to 0.994 (CI 0.988 to 0.999) at second sampling (n=453, p<0.01); with no differences between sites. Primary endpoint rate for the 223 patients (74%) with normal cTnI on presentation was lower than the 79 patients (26%) with cTnI>0.01 ug/l (5.9% vs. 42.3%, p<0.0001). The relative risk for the >0.01 ug/l group was 8.9 (CI 4.6 to 17). CONCLUSION: The VIDAS cTnI assay is a sensitive diagnostic method for the early detection of MI and predicts increased risk for adverse events in patients with symptoms suggestive of ACS.